Description
(AWP Alliance News) - Galderma raised its 2026 net sales growth forecast to 22.5%-23.5% at constant currency from 19%-21%, citing sustained strong momentum. It maintained its core EBITDA margin outlook at approximately 26% at constant currency.
Nine-month net sales reached USD 4.77 billion, up 25.1% at constant currency, with volume the primary growth driver. Therapeutic Dermatology led growth, with sales rising 64.4% at constant currency.
https://docs.publicnow.com/32CDAF89FACF59FCD3CE0B0554313B2955F2CF83
Disclaimer: This news brief was created using generative artificial intelligence. Galderma Group AG published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.
